Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: A systematic review and meta-analysis

• Published in: Diabetes research and clinical practice Vol. 147; pp. 1 - 8
• Main Authors: Cao, Yanchao, Yan, Liqiu, Guo, Nan, Yu, Na, Wang, Yunfei, Cao, Xufen, Yang, Shuping, Lv, Fengfeng
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 01.01.2019
• Subjects: Cardiovascular disease; Cardiovascular mortality; Meta-analysis; Non-high-density lipoprotein cholesterol; Cardiovascular disease; Non-high-density lipoprotein cholesterol; Cardiovascular mortality; Meta-analysis
• ISSN: 0168-8227; 1872-8227
• DOI: 10.1016/j.diabres.2018.11.002

•Conflicting results have reported on the association of non-HDL-C with CVD risk.•The general population with the highest non-HDL-C level increased by 62% CVD risk.•Type 2 diabetes patients with the highest non-HDL-C level increased by 99% CVD risk.•Higher non-HDL-C level was not associated with cardiovascular death risk in both populations.•Optimal cutoff value of non-HDL-C for predicting CVD should be further explored. To examine the relationship of non-high-density lipoprotein cholesterol (non-HDL-C) level with cardiovascular disease (CVD) risk in type 2 diabetes patients and the general population by conducting a meta-analysis. We made a comprehensive literature search for relevant observational studies investigating the relationship of non-HDL-C level with CVD risk in the general population and type 2 diabetes patients using the PubMed and Embase databases. Pooled risk ratio (RR) with 95% confidence intervals (CI) was calculated for the highest versus the reference lower non-HDL-Cl. A total of 13 studies with 156,381 individuals were included. The pooled RR of CVD was 1.59 (95% CI 1.46–1.72) in the general population and 1.99 (95% CI 1.57–2.51) in type 2 diabetes patients. Subgroup analysis showed the similar effect of non-HDL-C on CVD risk between men (RR1.98; 95% CI 1.70–2.30) and women (RR 1.63; 95% CI 1.35–1.96). However, elevated non-HDL-C was not associated with higher risk of cardiovascular mortality in the general population (RR 1.64; 95% CI 0.96–2.80) and type 2 diabetes patients (RR 1.08; 95% CI 0.57–2.07). Elevated non-HDL-C level is associated with an increased risk of CVD in the general population and type 2 diabetes patients.